Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST
Journal of Neuroendocrinology · 2023
DOI: 10.1111/jne.13311 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuroendocrinology, 2023. Verfasst von Louis de Mestier und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreatology and Digestive Oncology, Université Paris-Cité, INSERM U1149, Beaujon University Hospital, Clichy, France. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Liver Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
RECIST 1.1 criteria are commonly used with computed tomography (CT) to evaluate the efficacy of systemic treatments in patients with neuroendocrine tumors (NETs) and liver metastases (LMs), but their relevance is questioned in this setting. We aimed to explore alternative criteria using different numbers of measured LMs and thresholds of size and density variation. We retrospectively studied patients with advanced pancreatic or small intestine NETs with LMs, treated with systemic treatment in the first‐and/or second‐line, without early progression, in 14 European expert centers. We compared time to treatment failure (TTF) between responders and non‐responders according to various criteria defined by 0%, 10%, 20% or 30% decrease in the sum of LM size, and/or by 10%, 15% or 20% decrease in LM density, measured on two, three or five LMs, on baseline (≤1 month before treatment initiation) and first revaluation (≤6 months) contrast‐enhanced CT scans. Multivariable Cox proportional hazard models were performed to adjust the association between response criteria and TTF on prognostic factors. We included 129 systemic treatments (long‐acting somatostatin analogs 41.9%, chemotherapy 26.4%, targeted therapies 31.8%), administered as first‐line (53.5%) or second‐line therapies (46.5%) in 91 patients. A decrease ≥10% in the size of three LMs was the response criterion that best predicted prolonged TTF, with significance at multivariable analysis (HR 1.90; 95% CI: 1.06–3.40; p = .03). Conversely, response defined by RECIST 1.1 did not predict prolonged TTF ( p = .91), and neither did criteria based on changes in LM density. A ≥10% decrease in size of three LMs could be a more clinically relevant criterion than the current 30% threshold utilized by RECIST 1.1 for the evaluation of treatment efficacy in patients with advanced NETs. Its implementation in clinical trials is mandatory for prospective validation. Criteria based on changes in LM density were not predictive of treatment efficacy. Clinical Trial Registration Registered at CNIL‐CERB, Assistance publique hopitaux de Paris as “E‐NETNET‐L‐E‐CT” July 2018. No number was assigned. Approved by the Medical Ethics Review Board of University Medical Center Groningen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pancreatology and Digestive Oncology, Université Paris-Cité, INSERM U1149, Beaujon University Hospital, Clichy, France.
- Department of Epidemiology and Biostatistics, Université Paris-Cité, Saint-Louis Hospital, Paris, France.
- Department of Radiology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
- Department of Medical Oncology, The Christie Hospital, Manchester, UK.
- Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
- Department of Radiology, Universitair Ziekenhuis Antwerpen, Edegem, Belgium.
ORCID-Profile: Clarisse Dromain, Uli Fehrenbach, Ivan Borbath, Wouter W de Herder, Andreas Selberherr, Marie-Pierre Vullierme
Zitieren
APA
de Mestier, L., Resche-Rigon, M., Dromain, C., Lamarca, A., La Salvia, A., de Baker, L., Fehrenbach, U., Pusceddu, S., Colao, A., Borbath, I., de Haas, R., Rinzivillo, M., Zerbi, A., Funicelli, L., de Herder, W. W., Selberherr, A., Wagner, A. D., Manoharan, P., De Cima, A., …, & Vullierme, M. P. (2023). Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST. Journal of Neuroendocrinology. https://doi.org/10.1111/jne.13311
Vancouver
de Mestier L, Resche-Rigon M, Dromain C, Lamarca A, La Salvia A, de Baker L, et al. Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST. Journal of Neuroendocrinology. 2023. doi:10.1111/jne.13311
BibTeX
@article{deMestier2023,
author = {de Mestier, Louis and Resche-Rigon, Matthieu and Dromain, Clarisse and Lamarca, Angela and La Salvia, Anna and de Baker, Lesley and Fehrenbach, Uli and Pusceddu, Sara and Colao, Annamaria and Borbath, Ivan and de Haas, Robbert and Rinzivillo, Maria and Zerbi, Alessandro and Funicelli, Luigi and de Herder, Wouter W and Selberherr, Andreas and Wagner, Anna Dorothea and Manoharan, Prakash and De Cima, Andrea and Lybaert, Willem and Jann, Henning and Prinzi, Natalie and Faggiano, Antongiulio and Annet, Laurence and Walenkamp, Annemiek and Panzuto, Francesco and Pedicini, Vittorio and Pitoni, Maria Giovanna and Siebenhuener, Alexander and Mayerhoefer, Marius E and Ruszniewski, Philippe and Vullierme, Marie-Pierre},
title = {Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST},
journal = {Journal of Neuroendocrinology},
year = {2023},
doi = {10.1111/jne.13311}
}
EUVIMED